黃秀芬 研究員級主治醫師
分子與基因醫學研究所
連絡電話：886-37-206166 ext. 35315
E-mail：sfhuang@nhri.edu.tw
學歷
1975-1983 M.D., College of Medicine, National Taiwan University
1989-1997 Ph.D., Institute of Pathology, National Taiwan University
經歷
|
2010 – present |
Investigator and Attending Physician, Division of Molecular and Genomic Medicine, National Health Research Institutes, Taipei, Taiwan |
|
2008 – present |
Adjunct Associate professor, Department of Pathology, Tsu-Chi University, Taipei, Taiwan |
|
2003 – 2010 |
Associate Investigator and Attending Physician, Division of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan |
|
2003 – 2008 |
Adjunct Associate professor, Department of Pathology, Taipei Medical University, Taipei, Taiwan |
|
2000 – 2003 |
Associate Professor of Pathology, School of Medicine, Chang-Gung University, Taoyuan, Taiwan |
|
2000 – 2002 |
Director of Anatomical Pathology, Department of Pathology, Chang-Gung Memorial Hospital, Taipei, Taiwan |
|
1999 – 2003 |
Attending Physician, Department of Pathology, Chang-Gung Memorial Hospital, Taipei, Taiwan |
|
1994 – 1995 |
Research Fellow, Department of Pathology, Brigham and Women’s Hospital & Harvard Medical School, Boston, U.S.A |
|
1990 – 1991 |
Clinical Fellow, Department of Pathology, Children’s Hospital in Boston & Harvard Medical School, Boston, U.S.A |
|
1989 – 1999 |
Attending Physician, Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan |
|
1989 – 1999 |
Instructor, Department of Pathology, National Taiwan University College of Medicine, Taipei, Taiwan |
研究興趣
黃博士是一位資深的病理醫師，尤其專長於肺臟，肝臟和兒科病理。到目前為止，她有多達220篇論文發表。黃博士的研究興趣是人體生物資料庫的建立和與實體瘤腫瘤的分子遺傳學研究，主要集中在肝細胞癌和肺癌。分子病理診斷也是她的專長，尤其專注於實體癌症和兒科腫瘤的分子診斷。
黃博士帶領的研究團隊是2004年亞洲第一個發表在非小細胞肺癌（NSCLC）患者有高EGFR突變率的研究團隊，這與EGFR酪氨酸激酶抑製劑吉非替尼的反應性有關。這一重要發現表明，台灣肺癌患者對這種新藥的反應率較高，並有利於延長生存期。在接下來的幾年裡，她的研究小組發表了20多篇EGFR突變或TKI相關的NSCLC論文。
黃博士也是在台灣和世界建立最大和最好的肝癌生物庫的關鍵人物，其中包括超過9,000名肝腫瘤患者（台灣肝癌網）的生物樣本。該生物庫已成為台灣所有肝癌研究人員最重要的資源。這個大型肝癌生物庫現在屬於NHRI Biobank。 NHRI Biobank還收集了2000多名肺癌患者。黃博士是NHRI Biobank的現任生物醫學主任。在2016年和2018年，她的研究小組發表了兩篇重要論文，詳細介紹了台灣肝癌網絡收集的3,843例HCC患者和411例NBNC HCC系列的詳細病毒標記研究，這兩篇文獻都是文獻中最詳細的HCC研究系列。
黃博士的研究團隊也對HBV相關的肝癌發生進行了大量研究。在台灣，乙型肝炎病毒（HBV）相關的肝細胞癌（HCC）患者HBV突變頻率非常高。這些突變可能在肝癌發生中起重要作用。通過異種移植動物研究，我們已經發現三種無義突變的乙型肝炎病毒S（HBS）基因具有致癌活性，尤其是sW182無義突變體。 sW182無義突變也是在HCC腫瘤組織中發現的最常見的無義突變。我們將使用體內動物方法通過流體動力學注射結合睡美容轉座酶介導的體細胞整合，來實現小鼠肝細胞中的sW182 *長期表達。 sW182無義突變體將在該動物模型中單獨表達或與宿主因子或環境因子組合表達，以研究它們在促進體內肝癌發生中的協同作用。
研究著作
肝癌 :
1. Huang SF (corresponding author), Hsu HC, Fletcher JA. Investigation of chromosomal aberrations in hepatocellular carcinoma by fluorescence in situ hybridization. Cancer Genet Cytogenet 1999;111:21-27.
2. Huang SF (corresponding author), Hsu HC, Chen JC, Chie WC, Lai PL.Tetrasomy 6 and 6q14 deletion are associated with better survival in hepatocellular carcinomas:: a fluorescence in situ hybridization study of 77 cases. Cancer Genet Cytogenet 2003 July;144:23-30.
3. Shiu-Feng Huang (corresponding author), Ya-Ting Chen, Wei-Chen Lee, Il-Chi Chang, Yu-Ting Chiu, Yu Chang, Hsiao-Chen Tu, Chiou-Hwa Yuh, Isao Matsuura, Liang-Yu Shih, Ming-Wei Lai, Hong-Dar Isaac Wu, Miin-Fu Chen, Chau-Ting Yeh. Identification of transforming hepatitis B virus S gene nonsense mutations derived from freely replicative viruses in hepatocellular carcinoma. PLoS ONE 2014, Feb.25; 9(2): e89753. doi:10.1371/journal.pone.0089753.
4. Shih Sheng Jiang*, Shiu-Feng Huang*(*equal contribution), Min-Syuan Huang, Yng-Tay Chen, Hsiang-Ju Jhong, Il-Chi Chang, Ya-Ting Chen, Jer-Wei Chang, Wen-Ling Chen, Wei-Chen Lee, Miin-Fu Chen, Chau-Ting Yeh, Isao Matsuura. Dysregulation of the TGFBI gene is involved in the oncogenic activity of the nonsense mutation of hepatitis B virus surface gene sW182*. Biochim Biophys Acta-molecular basis of disease. Biochimica et biophysica acta –molecular basis of disease (BBA-MBD), 2014, July, 1842(7):1080-1087. [Epub ahead of print on 2014 Mar 22.]
5. Shiu-Feng Huang (corresponding author), Hong-Dar Isaac Wu, Ya-Ting Chen, Saravana R. K. Murthy, Yu-Ting Chiu, Yu-Chang, Xuyu Yang, Il-Chi Chang, Y. Peng Loh. Carboxypeptidase E is a prediction marker for tumor recurrence in the early stage hepatocellular carcinoma. Tumor Biology 2016, Jan. 23, published online. Doi: 10.1007/s13277-016-4814-7.
6. Il-Chi Chang, PhD.,Shiu-Feng Huang, MD.,PhD.(corresponding author), Pei-Jer Chen, MD.,PhD.,Chi-Ling Chen, PhD.,Chao-Long Chen, MD.,Cheng-Chung Wu, MD., Cheng-Chung Tsai, MD.,Po-Huang Lee, MD., Miin-Fu Chen, MD., Chuan-Mo Lee, MD., Hsien-Chung Yu, MD., Gin-Ho Lo, MD., Chau-Ting Yeh, MD.,PhD., Chih-Chen Hong, PhD., Hock-Liew Eng, MD., John Wang, MD., Hui-Hwa Tseng, MD., Cheng-Hsiang Hsiao, MD., Hong-Dar Isaac Wu, PhD., Tseng-Chang Yen, PhD., Yun-Fan Liaw MD. The hepatitis viral status in patients with hepatocellular carcinoma – a study of 3843 patients from Taiwan Liver Cancer Network. Medicine (Baltimore) 2016 Apr;95(15):e3284. April 17.
肺癌 :
7. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF. High Frequency of EGFR mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clinical Cancer Research 2004;10(24):8195-203.
8. Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT, Tsai SF, Huang SF (Corresponding author). Distinctive Activation Patterns in Constitutively Active and Gefitinib-Sensitive EGFR Mutants. Oncogene 2006 Feb 23, 25:1205-1215, Epub 2005,Oct.3
9. Hsieh MH, Fang YF, Chang WC, Kuo HP, Lin SY, Liu HP, Liu CL, Chen HC, Ku YC, Chen YT, Chang YH, Chen YT, Hsi BL, Tsai SF, Huang SF (corresponding author). Complex Mutation Patterns of Epidermal Growth Factor Receptor Gene Associated with Variable Responses to Gefitinib Treatment in Patients with Non-Small Cell Lung Cancer. Lung Cancer 2006; Sep. 53:311-322, Epub 2006, Jul 24.
10. Chang JW-C, Liu HP, Hsieh MH, Fang YF, Hsieh MS, Hsieh JJ, Chiu YT, Tsai HY, Chen YH, Chen YT, Hsu HY, Chen YT, Tsai SF, Chen YR, Hsi BL, Huang SF (corresponding author). Increased Epidermal Growth Factor Receptor (EGFR) Gene Copy Number is Strongly Associated with EGFR Mutations and Adenocarcinoma in Non-Small Cell Lung Cancers: A Chromogenic in situ Hybridization Study of 182 patients. Lung Cancer 2008, September;61:328 -339.
11.Wu CC, Hsu HY, Liu HP, Chang JWH, Chen YT, Hsieh WY, Hsieh JJ, Hsieh MS, Chen YR, Huang SF (corresponding author). Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of lung in Taiwan and its implication. Cancer, 2008 Dec 1;113(11):3199-208.
12. Liu Hp, Wu HD, Chang JWH, Wu YC, Yang HY, Chen YT, Hsieh WY, Chen YT, Chen YR, Huang SF (corresponding author). Prognostic implications of EGFR and KRAS gene mutations, and EGFR gene copy numbers in Surgically Resectable Non-Small Cell Lung Cancer Patients in Taiwan. J Thorac Oncol 2010;5:1175-1184.
13. Chen YT, Liu Hp, Chang JWH, Wu YC, Yu TF, Hsieh JJ, Chen YR, Huang SF (corresponding author). Clinical implications of high MET gene dosage in non-small cell lung cancer patients without prior tyrosine kinase inhibitor treatment. J Thorac Oncol 2011 Dec;6:2027- 2035.
14. Yi-Cheng Wu, MD, Il-Chi Chang, PhD, Chi-Liang Wang, MD, Tai-Di Chen, MD, Ya-Ting Chen, MS, Hui-Ping Liu, MD, Yen Chu, PhD. Yu-Ting Chiu, BS, Tzu-Hua Wu, MS, Li-Hui Chou, PhD, Yi-Rong Chen, PhD, Shiu-Feng Huang, MD, PhD. (corresponding author) Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS ONE 2013 August 7, 8(8): Article number e70839. doi:10.1371/journal.pone.0070839.
15. Chi-Hwa Yang, Hsiao-Chin Chou, Yu-Ning Fu, Chi-Ling Yeh, Hui-Wen Cheng, Il-Chi Chang, Ko-Jiunn Liu, Gee-Chen Chang, Ting-Fen Tsai, Shih-Feng Tsai, Hui-Ping Liu, Yi-Cheng Wu, Ya-Ting Chen, Shiu-Feng Huang (corresponding author), Yi-Rong Chen. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. Biochim Biophys Acta (BBA-MBD). 2015 Jul;1852(7):1540-9
實驗室成員
